Clinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Document first published:
Page updated:
Topic:
Publication type:

The combination of dabrafenib and trametinib is recommended to be available as a routine commissioning treatment option for anaplastic thyroid cancer (ATC) within the criteria set out in this document.

Document

Clinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Clinical commissioning policy: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

  • PDF
  • 145 KB

Document

Clinical panel report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Clinical panel report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

  • PDF
  • 52 KB

Document

Clinical priorities advisory group summary report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Clinical priorities advisory group summary report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

  • PDF
  • 92 KB

Document

Public health evidence report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Public health evidence report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

  • PDF
  • 30 KB

Document

Engagement report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Engagement report: Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

  • PDF
  • 86 KB

Document

Equality and Health Inequalities Impact Assessment (EHIA): Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

Equality and Health Inequalities Impact Assessment (EHIA): Dabrafenib and trametinib in the treatment of patients with BRAF-mutated anaplastic thyroid cancer

  • PDF
  • 97 KB

Document

NHS England Evidence Review: Dabrafenib and trametinib for anaplastic thyroid cancer with BRAF mutation

NHS England Evidence Review: Dabrafenib and trametinib for anaplastic thyroid cancer with BRAF mutation

  • PDF
  • 411 KB
  • 38 pages

Summary

NHS England URN: 2110